HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

ACC 2025 data strengthen the case for icosapent ethyl on top of low LDL

Louis Nervegna · May 21, 2025 · ♥ 7 reactions · 0 comments · original Facebook post
PCSK9, ezetimibe & newer drugsHeart attack, stroke & procedures
AI summary & key facts

Louis notes ACC 2025 studies support purified EPA (icosapent ethyl) lowering heart attack and stroke even at LDL target, especially with elevated triglycerides.

Several studies presented at the 2025 meeting of the American College of Cardiology strengthen the case that purified EPA from fish oil (Icosapent Ethyl) lowers risk of heart attacks and strokes.

This is true even in patients who are already at an appropriately low LDL target, especially if they still have elevated triglycerides.

radcliffecardiology.comAcc highlights updates icosapent ethyl and cardiometabolic riskradcliffecardiology.com

#epaHD #fishoilHD #omega3HD #triglyceridesHD #accHD

Research cited

← newer: NLA consensus: ApoB testing is a better predictor than LDL-Colder: LDL targets by risk: below 55 for very high risk down to bel →